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Antiproliferative effects of 
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Alessandra Luchini3,4, Michele Caraglia2, Luigi Paduano3,5, Daniela Montesarchio3 & 
Rita Santamaria1
Looking for new metal-based anticancer treatments, in recent years many ruthenium complexes have 
been proposed as effective and safe potential drugs. In this context we have recently developed a novel 
approach for the in vivo delivery of Ru(III) complexes, preparing stable ruthenium-based nucleolipidic 
nanoaggregates endowed with significant antiproliferative activity. Herein we describe the cellular 
response to our ruthenium-containing formulations in selected models of human breast cancer. By  
in vitro bioscreens in the context of preclinical studies, we have focused on their ability to inhibit breast 
cancer cell proliferation by the activation of the intrinsic apoptotic pathway, possibly via mitochondrial 
perturbations involving Bcl-2 family members and predisposing to programmed cell death. In addition, 
the most efficient ruthenium-containing cationic nanoaggregates we have hitherto developed are 
able to elicit both extrinsic and intrinsic apoptosis, as well as autophagy. To limit chemoresistance 
and counteract uncontrolled proliferation, multiple cell death pathways activation by metal-based 
chemotherapeutics is a challenging, yet very promising strategy for targeted therapy development in 
aggressive cancer diseases, such as triple-negative breast cancer with limited treatment options. These 
outcomes provide valuable, original knowledge on ruthenium-based candidate drugs and new insights 
for future optimized cancer treatment protocols.
Metallodrugs exhibit a wide range of interesting biological activities, including transition metal-based com-
pounds proved to be effective anticancer agents1–3. Cisplatin and its analogues have hitherto dominated the field 
of inorganic compounds endowed with high relevance in cancer treatment, so that platinum-based drugs are 
currently the most widely used chemotherapeutics4. Activation of cellular apoptosis triggered by DNA targeting 
seems to be the main determinant in causing bioactivity of cisplatin and its derivatives5. Based on the success 
of platinum-based anticancer drugs and aiming at overcoming the drawbacks related to their clinical use - 
i.e. high general toxicity, chemoresistance and inactivity against some cancer types - since the last decades a 
variety of novel metal-based chemotherapeutics are being investigated6,7. Within the intense search for more 
effective cytotoxic metallodrugs, ruthenium complexes have emerged among the most promising alternatives 
to platinum-based clinically validated anticancer agents8. This accounts for the large amount of current reports 
on novel candidate drugs investigated within the frame of a potential “ruthenotherapy”. Indeed, a number of 
ruthenium complexes, which exhibit interesting physico-chemical and biochemical properties, associated with 
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low toxicity profiles, have been recently identified and intensively studied9,10. Many ruthenium complexes have in 
fact shown selective bioactivity, as well as the ability to overcome the resistance encountered with platinum-based 
drugs, ranking them as strong antitumoral candidates in a rational drug discovery approach11. Among these, 
ruthenium(III) compounds behave as valid prodrugs with somehow limited side-effects11, being likely activated 
to the more reactive and cytotoxic ruthenium(II) derivatives within the reducing microenvironment of solid 
tumours12. Along with ligands release and/or substitution - which occurs rapidly under physiological conditions 
in vitro and in vivo - the biological reduction of ruthenium(III) complexes is a possible process, especially in high 
proliferating cells, thereby promoting a unique activation process of this kind of metal-based drug in tumour 
tissues12. Nevertheless, in the general uncertainty concerning their mechanism of action, it cannot be excluded 
that Ru(III) complexes, properly transported into tumour cells, can interact in their original redox status with 
potential molecular targets. Furthermore, the possibility to be transported by the transferrin/transferrin receptor 
(Tf/TfR) network in place of iron, might allow for a natural ruthenium accumulation within cancer cells, typically 
requiring high iron amounts to accommodate for their rapid proliferation13,14.
Despite the positive outcomes throughout advanced preclinical and clinical evaluations of the anticancer 
ruthenium(III)-based compounds NAMI-A15 - the most advanced candidate drug having completed Phase II 
clinical trials - and KP101916 (NKP1339, the sodium salt of KP1019, is described to be ready for clinical appli-
ance17), various drawbacks have been observed, mainly related to their limited stability in physiological condi-
tions, impairing both their general pharmacokinetic and pharmacodynamic profiles18. In addition to interfering 
with the internalization process into targeted cancer cells, degradation events can also limit the therapeutic effec-
tiveness, thereby becoming a central issue that has claimed a reconsideration of the efficacy of low molecular 
weight ruthenium complexes currently in preclinical or clinical studies19. Additionally, the lack of convincing 
evidences on their biological mode of action, as well as on targets identification, has significantly limited their 
further development20,21. Aiming at improving the stability of the ruthenium(III)-based drugs in biological envi-
ronments, as well as their suitability for biomedical applications, we have recently proposed an innovative strategy 
for their transport in vivo incorporating them within liposomial aggregates. Starting from a core molecular scaf-
fold based on a ruthenium complex inspired to NAMI-A, named AziRu showing per se higher in vitro cytotox-
icity than NAMI-A22,23, we have developed a mini-library of highly functionalized amphiphilic ruthenium(III) 
complexes, including differently decorated nucleolipids (see Fig. 1). The resulting nucleolipidic Ru(III) com-
plexes (named ToThyRu, HoThyRu and DoHuRu) are endowed with a marked propensity for self-aggregation 
in aqueous solutions and high in vitro antiproliferative activity against human cancer cells, thus proving to be 
promising lead compounds for future in vivo studies. Moreover, on the lookout for biomimetic nanosystems, 
stable nucleolipidic Ru(III) complexes were produced by co-aggregation with either the zwitterionic phospho-
lipid POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) or the cationic lipid DOTAP (1,2-dioleoyl-3-tr
imethylammoniumpropane chloride). The final nanoaggregates - which exhibit liposomial structure and have 
been subjected to an in-depth microstructural characterization - are ad hoc designed to present high stability 
under physiological conditions as well as to transport high ruthenium amounts in cells, thereby ensuring more 
effective metal-based treatments24–27. Indeed, recent in vitro bioactivity investigations have shown the great 
potential of our biocompatible ruthenium-containing liposomes as active antineoplastic agents against human 
carcinoma cells of different histological origin24. Of special interest have been the results obtained on estrogen 
and progesterone receptor positive MCF-7 adenocarcinoma cells, an in vitro model reflecting to a large extent 
the features of luminal breast cancer cells in vivo, worldwide the most common invasive cancer in women. Most 
remarkably, liposomes loaded with the Ru(III)-containing nucleolipids have shown a promising selectivity 
towards cancer cells in bioscreens in vitro19,22,25–27.
Figure 1. Molecular structures of Ru(III)-containing complexes. The investigated Ru(III) nucleolipidic 
complexes (a) ToThyRu and (b) DoHuRu, along with the low molecular weight Ru(III) complex (c) AziRu.
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To expand knowledge on these compounds so to optimally develop ruthenium-based candidate drugs, mech-
anisms including interaction with DNA and induction of apoptosis have been investigated, but little has been 
hitherto explored on their overall modes of action as well as on biomolecular targeting14. Thus, in continuation 
with our previous studies, we have herein investigated in-depth the anticancer profile and mode of action of 
Ru(III)-containing liposomes. In particular, by focusing on well-established breast cancer cell lines as in vitro 
models for human mammary tumours, we here describe via preclinical bioscreens how nucleolipidic ruthenium 
complexes are able to activate specific molecular cell death pathways, thereby interfering with cancer cells growth 
and proliferation. We also provide evidence that could strengthen novel drug-discovery strategies and ultimately 
lead to more selective ruthenium-based anticancer agents.
Results
In vitro bioscreens for anticancer activity. The antiproliferative properties of the liposomes containing 
the Ru(III)-nucleolipids were screened on human breast cancer models by means of selected mammary malig-
nant cells endowed with different phenotypic and/or genotypic features and different replicative and/or invasive 
potential (MCF-7, CG-5, MDA-MB-231, MDA-MB-468 and MDA-MB-436 cell lines). The concentration-ef-
fect curves (Fig. 2a) - here reported in terms of a “cell survival index” which combines the measurements of 
cell number and viability - show a typical concentration-dependent sigmoid trend yielding IC50 values in the 
low micromolar range. According to the IC50 values (see Table 1), the ToThyRu/DOTAP and DoHuRu/DOTAP 
formulations are the most effective in reducing the proliferation of all the used cell lines. This result, consistent 
with our previous reports, is likely associated to the positive charge of DOTAP formulations which can promote 
the interaction with the plasma membranes allowing a faster and quantitative drug cellular uptake19. Moreover, 
in relation to their effectiveness in vitro, there are no significant differences between the ToThyRu and DoHuRu 
nucleolipidic Ru(III) complexes used in our liposomial formulations, consistently with the rationale that the 
ruthenium center is the bioactive species, and the nucleolipids are simply carrier molecules24. IC50 data normali-
zation in favour of the actual ruthenium content enclosed in ToThyRu/DOTAP and DoHuRu/DOTAP liposomes 
(15% mol/mol), leads up to values of IC50 of about 3–4 μ M in CG-5 cells and of about 10 μ M in MCF-7 cells, sug-
gestive of a marked antiproliferative bioactivity in vitro. Overall, the calculated ruthenium IC50 values for DOTAP 
liposomes are in the low micromolar range (≤ 20 μ M), similar or lower than those measured for cisplatin used in 
the same experimental conditions as a reference drug. All the breast cancer cells used in this screening are there-
fore sensitive to the action of metal-based drugs. The ruthenium IC50 values relative to cell growth inhibition in 
the presence of ToThyRu/POPC and DoHuRu/POPC formulations are also relevant, reaching values below 20 μ M 
as in the case of MDA-MB-468, MCF-7 and CG-5 cancer cells. Looking further at IC50 values, the “naked” low 
molecular weight Ru(III) complex AziRu exhibits a milder antiproliferative activity on the same breast cancer 
cells, showing IC50 values constantly greater than 250 μ M. These values are generally in agreement with those 
reported in the literature for the antimetastatic NAMI-A28, and once more highlight the critical importance of 
the delivery strategy to ensure the drug stability in the extra-cellular environment, a quantitative transport across 
the membranes and the bioavailability at the biological targets. Noteworthy, the bioactivity potentiating factors 
calculated as the ratio of IC50 values of the Ru(III)-containing liposomes with respect to the IC50 of AziRu, reach 
values of more than 20 in terms of antiproliferative ability27.
Cellular morphological changes. Monitoring the cellular morphological changes over time can provide 
an additional support to the antiproliferative effects produced by ruthenium-based nanoaggregates. Throughout 
the in vitro trials, imaging end-points were collected by light microscopy from cells to assess cellular morpholog-
ical changes induced by drug administration. Microphotographs in Fig. 2b of MCF-7 and MDA-MB-231 breast 
adenocarcinoma cells, nowadays among the most reliable in vitro models of breast cancer, in the presence of 
DoHuRu/POPC and DoHuRu/DOTAP (at their IC50 concentrations for 48 and 72 h) are suggestive of the char-
acteristic cell shrinkage as well as loss of cell-cell contact that accompanies apoptosis occurrence. Moreover, after 
in vitro treatments cells were morphologically examined at a higher magnification by a phase-contrast micro-
scope for autophagic vacuoles formation. As shown in Fig. 2c, in addition to apoptotic hallmarks, autophagic 
vacuoles clearly appear when MCF-7 cells were treated with the DoHuRu/DOTAP liposomes for 48 h at IC50 
concentration, providing a morphological support of autophagy activation. These observations were further con-
firmed by FACS analysis, discussed below. Thus, the AziRu in vitro treatment by the DoHuRu/POPC liposome 
seems to trigger exclusively apoptosis, whereas the one with the cationic DoHuRu/DOTAP seems to simultane-
ously activate apoptosis and autophagy.
Pro-apoptotic effects in breast cancer cells. Changes both in the cell morphology and in the mon-
olayers appearance suggest that liposomes containing the nucleolipidic Ru(III)-complexes might have chemo-
therapeutic effects in human breast cancer initiating cells towards specific cell death pathways. The evaluation of 
apoptosis induction via FACS analysis has revealed that both DoHuRu/POPC and DoHuRu/DOTAP formula-
tions are able to induce remarkable pro-apoptotic effects on MCF-7 cells and MDA-MB-231. In fact, as depicted 
in Fig. 3a,c with reference to MCF-7 cells, the 46% of total cell population is in advanced stage of apoptosis follow-
ing 48 h of exposure to IC50 concentrations of DoHuRu/DOTAP; further 24 h of treatment results in the 82% of 
cell population in late apoptosis phase. Milder pro-apoptotic effects, but nonetheless of significance, are detected 
in the case of DoHuRu/POPC treatment, leading after 48 h to about 36% of total MCF-7 cell population in early 
apoptosis and to a 37% in late apoptosis after 72 h. As a further validation of these data, no significant signals of 
apoptosis perturbation, such as an increased necrosis, were detectable by FACS analysis. A similar distribution 
of cell population among the different apoptotic stages has been observed by investigating the effects of lipos-
omes containing nucleolipidic Ru(III)-complexes on MDA-MB-231 cells (see Fig. 3b,d), confirming the increased 
in vitro efficacy - especially as a trend over time - of the cationic nanoaggregates (i.e., the DoHuRu/DOTAP ones) 
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with respect to the zwitterionic POPC ones. This scenario is fully consistent with our previous studies19,27. As a 
result of different cellular uptake kinetics, ruthenium-containing cationic liposomes (DoHuRu/DOTAP) induce 
faster biological effects by way of cellular apoptosis activation than those dependent by the neutral liposomes 
(DoHuRu/POPC).
Figure 2. Cell survival index and cytomorphological alterations on cell monolayers. (a) Cell survival index, 
evaluated by the MTT assay and monitoring of live/dead cell ratio for MCF-7, MDA-MB-231, MDA-MB-436, 
MDA-MB-468, and CG-5 cell lines following 48 h of incubation with the indicated concentration (the range 
1 → 1000 μ M has been explored, the one 1 → 250 μ M is shown) of AziRu, and of the ruthenium-containing (15% mol/
mol) POPC formulations (ToThyRu/POPC and DoHuRu/POPC) and DOTAP formulations (ToThyRu/DOTAP 
and DoHuRu/DOTAP), as indicated in the legend. Data are expressed as percentage of untreated control cells and 
are reported as mean of five independent experiments ± SEM (n = 30). (b) Representative microphotographs at a 
200 × magnification (20 × objective and a 10 × eyepiece) by phase-contrast light microscopy of MCF-7 (left panels) 
and MDA-MB-231 (right panels) breast cancer cells treated for 48 and 72 h with ruthenium IC50 micromolar 
concentrations of DoHuRu/POPC (18.9 and 14.7 μ M, respectively) and DoHuRu/DOTAP liposomes (10.3 and 
12.1 μM, respectively), showing the cellular morphological changes and the cytotoxic effects on cell monolayers. 
The shown images are representative of three independent experiments. (c) Representative microphotographs 
of untreated (left panel) and 48 h DoHuRu/DOTAP treated (right panel) MCF-7 cells by phase-contrast light 
microscopy at a 600 × magnification (30 × objective and a 20 × eyepiece). DoHuRu/DOTAP (at IC50 concentration) 
induces the formation of autophagic vacuoles detectable in cell cytoplasm. Inset: higher magnifications of MCF-7 cells 
before and after treatment.
www.nature.com/scientificreports/
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DNA fragmentation in MCF-7 and MDA-MB-231. It is generally accepted that DNA damage and sub-
sequent induction of apoptosis is the primary cytotoxic mode of action of cisplatin and other metal-based anti-
proliferative drugs. In addition to shrinkage and fragmentation of the cells and nuclei, the apoptotic process is 
accompanied by degradation of the chromosomal DNA into nucleosomal units. Indeed, late events of apoptosis 
typically lead to DNA cleavage, resulting in a “ladder” formation detectable by agarose gel electrophoresis. To ver-
ify apoptosis induction in breast cancer cells in a direct manner, we analyzed DNA degradation on genomic DNA 
samples obtained from treated cells. As depicted in Fig. 3e, though with a non-canonical nuclear fragmentation 
pattern in MCF-7 due to inherent caspase-3 expression deficiency, the DNA damage markedly increased in cells 
exposed to both DoHuRu/POPC and DoHuRu/DOTAP for 48 h at IC50 doses. Moreover, the typical internucleo-
somal DNA laddering of cell undergoing apoptosis clearly appeared in MDA-MB-231 cells, with a fragmentation 
pattern similar to that induced by IC50 doses of cisplatin in vitro, herein used as positive control29.
Apoptotic-related proteins in MCF-7 and MDA-MB-231 breast cancer cells. Given that the expres-
sion profile of pro-apoptotic proteins is a central determinant for the death mode induced by ruthenium-based 
drugs, we analyzed the expression of proteins linked to the two main pathways that control mammalian apop-
tosis, i.e. the extrinsic (or death receptor) and intrinsic (or mitochondrial) apoptotic pathways. As determined 
by Western blot analysis reported in Fig. 4a,c,e, protein extracts from MCF-7 exposed for 48 and 72 h to IC50 
concentrations of DoHuRu/POPC and DoHuRu/DOTAP showed a remarkable increase in caspase-9 activity 
compared with control, whereas in the same experimental conditions no caspase-8 activation was detectable. 
Indeed, the activation of pro-caspase-9 involves intrinsic proteolytic processing, resulting in the production of an 
active p35 subunit. Moreover, as clearly detectable by immunoblot, an additional cleavage occurred producing a 
large p37 subunit which is known to amplify the apoptotic response. On the other hand, full length pro-caspase-8 
expression was not affected by in vitro treatments. Taken together, these results suggest a ruthenium-dependent 
activation of the apoptotic mitochondrial pathway, wherein Bax and Bid are key cell death factors increasing 
mitochondrial permeability and release of cytochrome c. Conversely, cell survival factor Bcl-2 inhibits actions 
of Bax and Bid on mitochondria30. In MCF-7 cells Bax was significantly increased and Bcl-2 decreased upon 
DoHuRu/POPC and DoHuRu/DOTAP treatment - a cellular response predisposing to apoptotis activation. These 
biological effects were time-dependent and more evident following in vitro treatment with the cationic DoHuRu/
DOTAP liposomes.
In the same way, ruthenium treatment in MDA-MB-231 breast cancer cells via DoHuRu/POPC and DoHuRu/
DOTAP in vitro administration at IC50 concentrations elicited caspase-9 activation after 48 h, and this anew 
was coupled to the simultaneous Bax and Bcl-2 up-regulation and down-regulation, respectively (Fig. 4b,d,f). 
Furthermore, in this breast cancer cell line DoHuRu/DOTAP seemed able to promote full length pro-caspase-8 
cleavage, as evidenced by the formation of the active p10 and p18 fragments. In turn, activated initiator caspases 
further process other caspase members, including caspase-3 and caspase-7, to initiate a caspase cascade, which 
generally leads to complete the programmed cell death process. In fact, the immunoblotting analysis performed 
on MDA-MB-231 cells exposed to Ru(III)-containing liposomes further revealed a marked proteolytic cleavage 
of the inactive proenzyme to activate caspase-3. Hence, the evaluation of apoptosis regulatory proteins in breast 
cancer models for the in vitro preclinical evaluation of ruthenium biological effects suggests the invariable induc-
tion of the mitochondrial apoptotic cell death pathway, but also the cell-specific activation of the extrinsic death 
pathway particularly in the case of the cationic nanoaggregate.
Interestingly, the treatment with either DoHuRu/POPC or DoHuRu/DOTAP alters the expression pro-
file of Bax and Bcl-2 proteins with respect to basal amounts, radically changing the Bax/Bcl-2 ratio. The Bax 
up-regulation and Bcl-2 down-regulation observed in concert following ruthenium action may predispose cells 
to apoptosis30.
Autophagy activation in MCF-7 and MDA-MB-231 breast cancer cells. In addition to apop-
tosis, cellular suicide can also be executed via non-apoptotic forms of programmed death such as autophagy. 
The simultaneous evaluation of apoptosis and autophagy by means of the herein used methods is not mutu-
ally exclusive, i.e. it is possible to ascertain the degree of autophagy independently from that of apoptosis. 
Cell lines
IC50 (μM ± SEM)
ToThyRu/POPC DoHuRu/POPC ToThyRu/DOTAP DoHuRu/DOTAP
AziRu cDDPTotal liposome Ru Total liposome Ru Total liposome Ru Total liposome Ru
MCF-7 185 ± 0.1 27.8 ± 0.1 126 ± 0.1 18.9 ± 0.1 74.6 ± 0.1 10.1 ± 0.1 67.3 ± 0.2 10.3 ± 0.2 >250 17 ± 1
MDA-MB-231 239 ± 3 35.8 ± 3 98 ± 1 14.7 ± 1 79.5 ± 0.2 10.8 ± 0.2 81 ± 0.3 12.1 ± 0.3  >250 19 ± 1.5
MDA-MB-436 > 250 > 37.5 245 ± 1 36.7 ± 1 110 ± 0.2 15.0 ± 0.2 130.9 ± 0.2 20.0 ± 0.2  >250 NA
MDA-MB-468 111.1 ± 0.1 15.7 ± 0.1 136 ± 0.8 20.4 ± 0.8 107.8 ± 0.1 14.7 ± 0.1 95 ± 0.1 14.2 ± 0.1  >250 24 ± 1
CG-5 138 ± 0.2 19.4 ± 0.2 204 ± 0.8 30.6 ± 0.8 30.1 ± 0.2 4.1 ± 0.2 21.5 ± 0.2 3.3 ± 0.2  >250 NA
Table 1.  IC50 values (μM) relative to the specified POPC and DOTAP ruthenium-containing liposomes, 
and to cisplatin (cDDP), used as cytotoxic reference drug, and to the naked AziRu complex in the listed 
breast cancer cell lines following 48 h of incubation. The ruthenium IC50 values corresponding to the effective 
metal concentration (15% mol/mol) carried by each nanoaggregate are reported as mean values ± SEM (n = 30). 
(NA = not assessed).
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Thus, to investigate whether DoHuRu/POPC and DoHuRu/DOTAP can also induce autophagy in MCF-7 and 
MDA-MB-231 cells, we have examined the formation of autophagic vacuoles using monodansylcadaverine 
(MDC), a selective autofluorescent dye for autolysosomes detection. Autolysosomes occurrence, which results 
Figure 3. Induction of apoptosis in MCF-7 and MDA-MB-231 breast cancer cells. Apoptosis was evaluated 
by FACS analysis, after cell labeling with propidium iodide (PI) and FITC-Annexin V. MCF-7 (a) and 
MDA-MB-231 (b) cells were both unlabeled and untreated (CTR−), labeled and not treated (CTR + ), treated 
with DoHuRu/POPC or with DoHuRu/DOTAP for 48 and 72 h using IC50 concentrations, as indicated. The 
lower left quadrants of each panels show the viable cells, which exclude PI and are negative for FITC-Annexin V 
binding. The upper left quadrants contain the non-viable, necrotic cells, negative for FITC-Annexin V binding 
and positive for PI uptake. The lower right quadrants represent the cells in early apoptosis, that are FITC-
Annexin V positive and PI negative. The upper right quadrants represent the cells in late apoptosis, positive for 
both FITC-Annexin V binding and for PI uptake. The experiments were performed at least three times with 
similar results. Quantitative analysis of viable, non-viable (necrotic), early and late apoptotic MCF-7 (c) and 
MDA-MB-231 (d) cells after 48 and 72 h of treatments are shown. Data are expressed as percentage of untreated 
control cells and are reported as mean of four independent experiments ± SEM (n = 24); ***p < 0.001 vs. control 
(untreated cells). (e) DNA fragmentation assay on MCF-7 and MDA-MB-321 cells treated or not (C) with IC50 
concentrations of DoHuRu/POPC (RuPOPC) and DoHuRu/DOTAP (RuDOTAP) for 48 h, and with IC50 doses  
(17 and 19 μ M, respectively) of cisplatin (cDDP) as the positive control for DNA fragmentation. After 
incubation, the DNA was extracted and visualized on 1.5% agarose gel as detailed in the Methods section. The 
lane in the middle corresponds to the molecular weight markers. The agarose gel is representative of three 
independent experiments.
www.nature.com/scientificreports/
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from lysosomes-autophagosomes fusion, exclusively characterizes late steps in the autophagic cell death pro-
cess. In order to verify this circumstance, cells were exposed for 48 and 72 h to ruthenium IC50 concentrations 
enclosed within DoHuRu/POPC and DoHuRu/DOTAP nanoaggregates (18.9 and 10.3 μ M, respectively for MCF-
7, 14.7 and 12.1 μ M, respectively for MDA-MB-231) and the quantitative evaluation of MDC staining by means of 
FACS analysis was performed (see Fig. 5). As a result of MDC accumulation and consistently with phase contrast 
cell imaging, the cationic DoHuRu/DOTAP formulation induced an evident increase in the Mean Fluorescence 
Intensity (MFI), in particular 4.3 and 5.8-fold higher at 48 and 72 h for MCF-7, and 3.9 and 5.3-fold higher for 
MDA-MB-231 than untreated control cells. These results indicate an increased formation of the MDC-labeled 
Figure 4. Apoptotic regulatory proteins in MCF-7 and MDA-MB-231 cells. Western blot analysis showing 
the effects of IC50 concentrations of DoHuRu/POPC and DoHuRu/DOTAP following 48 and 72 h of incubations 
in MCF-7 (a) and MDA-MB-231 (b) cells on caspases-3, -8 and -9 expression and activation, and on Bax and 
Bcl-2 expression, to characterize the apoptotic response. Shown are blots representative of four independent 
experiments. After chemoluminescence, the bands resulting from MCF-7 (c,e) and MDA-MB-231 (d,f) cell 
extracts were quantified by densitometric analysis and plotted in line (solid and dotted line for Bax and Bcl-2 
proteins, respectively) and bar (caspases-3, -8 and -9) graphs as percentage of control in relation to the used 
ruthenium-containing nanoaggregate, as indicated. Shown are the average ± SEM values of four independent 
experiments. The anti-tubulin antibody was used to standardize the amounts of proteins in each lane. **p < 0.01 
vs. control cells; ***p < 0.001 vs. control cells.
www.nature.com/scientificreports/
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vacuoles after ruthenium treatment via DoHuRu/DOTAP cationic liposomes and suggest the activation of auto-
phagy in presence of apoptosis. Conversely, by using the zwitterionic DoHuRu/POPC liposomes, no significant 
autolysosomes formation was detected, at least up to 72 h.
Discussion
Innovative anticancer drugs with new molecular mechanisms of action are essential in chemotherapeutic treat-
ment to kill specific cancer types, and to overcome toxic side effects as well as chemoresistance31. Current research 
efforts are focused on a deeper understanding of the cellular response and/or resistance to anticancer treatments, 
including the role of cell death pathways activation, such as apoptosis and autophagy, by chemotherapeutics32. 
Recently, we have developed new biocompatible ruthenium-based nanosystems, proved to be particularly 
effective against specific cell lines derived from human solid tumours19,22,24–27. Starting from these encourag-
ing data, in the present work we have first confirmed their efficacy focusing on a panel of human tumour cells 
arising from breast cancer. At the moment, the endocrine-responsive (ER) breast adenocarcinoma MCF-7 and 
the triple-negative breast adenocarcinoma (TNBC) MDA-MB-231 cell models account for the great majority of 
investigations on breast cancer cells and are considered the most reliable in vitro models of breast cancer together 
with their variants CG5, and MDA-MB-436 and MDA-MB-468, respectively33,34. All these cells are sensitive to 
cisplatin in vitro, so that cisplatin is used in standard first line treatment protocols for many breast cancers, often 
in combination with other drugs, such as taxanes, vinca alkaloids, and 5-fluorouracil, resulting in synergistic 
or additive effects. Therefore, classical chemotherapy is currently the only drug-based option in the therapeutic 
armamentarium, and metal-based chemotherapy is also emerging as an upcoming treatment modality especially 
in TNBC35. Although new types of ruthenium complexes with superior anticancer activity in vitro have been 
meanwhile reported36, the induction of comparable or even greater cytotoxic effects than cisplatin have been 
herein confirmed for nucleolipidic Ru(III) formulations. Then, aiming at an in-depth investigation of their mode 
of action, we have shown that amphiphilic ruthenium complexes, properly delivered by suitable nano-systems, 
are able to kill cancer cells by activating specific apoptotic processes, coupled in some cases to cellular autophagy. 
Indeed, in the last decade many different ruthenium compounds have been tested for their anticancer properties. 
However, all the reported studies have not clearly evidenced a unique mode of action at cellular level, nor unam-
biguously defined a specific mechanism of action at molecular level10,21,24. In-depth bioanalytical studies have 
been so far performed especially for cisplatin, which have validated nuclear DNA as the main final drug target 
causing adducts formation and DNA damage, leading to cell division inhibition and cytotoxicity5. In analogy 
with cisplatin, some of us have recently demonstrated that also AziRu and NAMI-A can interact with DNA model 
systems, with Ru(III) ions being incorporated into oligonucleotide structures via stable linkages37. However, since 
an increasing number of evidences demonstrate that both ruthenium(II) and (III)-based drugs are able to interact 
with both intra- and extra-cellular protein targets, currently other molecular mechanisms of action cannot be 
excluded9,38.
Beyond molecular targeting, we have observed an invariable activation of programmed cell death pathways 
which confirms that the primary mode of action in breast cancer models of AziRu via DoHuRu/POPC and 
DoHuRu/DOTAP formulations is the induction of apoptosis. These data are largely in accordance with several 
reports highlighting the occurrence of distinct hallmarks of apoptosis after ruthenium administration in vitro16,39. 
Figure 5. Autophagy activation in MCF-7 and MDA-MD-231 breast cancer cells. Quantitative flow 
cytometric analysis of autophagosomes formation (MDC incorporation) in MCF-7 (a) and MDA-MD-231 
(b) breast cancer cells, unlabeled and untreated (CTR−), labeled and untreated (CTR+ ), treated with 
IC50 concentrations of DoHuRu/POPC or with DoHuRu/DOTAP for 48 and 72 h, as indicated. The main 
fluorescence intensities (MFIs) were calculated, as described in ‘Materials and Methods’. In the corresponding 
bar graphs, values are expressed as percentage of control cells and are reported as mean of four independent 
experiments ± SEM (n = 24); ***p < 0.001 vs. control (untreated cells).
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Cellular morphological changes and DNA fragmentation provided additional evidence of an apoptosis-inducing 
activity at the basis of the anticancer properties of AziRu. The regulation of apoptotic cell death orchestrated by 
intracellular caspases plays a fundamental role in the response to chemotherapeutics, as evasion of apoptosis is 
one of the central features of malignant progression as well as of drug resistance. Indeed, survival of malignant 
mammary cells is a key event in disease occurrence and progression, but also in therapy failure and chemore-
sistance development40. Physiological mammary cells growth is controlled by a balance between cell proliferation 
and apoptosis. A large body of evidence has clarified that tumour growth is not just a result of uncontrolled 
proliferation but also of reduced apoptosis, so that the balance between proliferation and apoptosis is crucial in 
determining the overall growth or regression of the tumour in response to chemotherapy41. Two main pathways 
of caspase activation have been described in mammalian cells, which result in final control of apoptosis. In the 
intrinsic pathway, typically activated by intracellular stress signals, pro-apoptotic cell death factors belonging 
to the Bcl-2 family increase mitochondrial permeability and release of cytochrome c, as well as of other pro-
teins from the intermembrane space of mitochondria. Apaf-1, a downstream mediator of apoptosis, along with 
cytochrome c, associates with caspase-9 in cytoplasm and leads to its activation42. The resulting apoptosome 
initiates a cascade of effector caspases, which include caspases-3, -6, and -7. In turn, the active caspase-3 triggers 
DNA fragmentation factor (Caspase-Activated DNase, CAD) and promotes DNA internucleosomal cleavage. All 
the formulations containing nucleolipidic Ru(III)-complexes we have tested activate the mitochondrial apoptotic 
cell death pathway in breast cancer cells, as highlighted by a remarkable activation of caspase-9. Interestingly, this 
occurs independently of the cell ability to complete apoptosis process via the executioner caspase-3, as demon-
strated by Ru-dependent activation of apoptosis in MCF-7. This adenocarcinoma model is known to be resist-
ant to some chemotherapeutics due to a deletion in the CASP-3 gene that leads to an inherited deficiency of 
caspase-343. Caspase-3 - commonly turned on by numerous death signals - cleaves a variety of important cellular 
proteins and is ultimately responsible for apoptotic DNA fragmentation. Despite the lack of caspase-3 expression, 
liposomes containing nucleolipidic Ru(III)-complexes have hitherto shown to be particularly effective on this 
in vitro model. It has been also reported that MCF-7 undergoes cell death by apoptotic stimuli in the absence 
of the typical DNA fragmentation, and recent observations further suggest that large and small DNA fragments 
coupled to even single-strand cleavage events occur during apoptotic death44. Consistently with our results, these 
observations have raised relevant questions on the degradation pattern of nuclear DNA in agarose gel electro-
phoresis detection, which remains controversial. However, morphological changes and MCF-7 cell death were 
independent of caspase-3 and may correlate with the activation of different apoptotic pathways and other effec-
tor caspases, such as caspase-6 or -7. As far as the activation of programmed cell death pathways is concerned, 
DoHuRu/DOTAP formulation seems capable to concurrently activate the two major pathways of apoptosis in 
a cell-specific mode. In fact, MDA-MB-231 cells, undergoing the apoptotic mitochondrial pathway after expo-
sure to DoHuRu/DOTAP, show an apparent proteolytic processing of pro-caspase-8 to form various fragments, 
including the active p18 and p10. The extrinsic pathway is activated by extracellular ligands able to bind to death 
receptors on the cell surface, which leads to the formation of the death-inducing signaling complex (DISC). This 
death receptor pathway is triggered by members of the death receptor superfamily such as CD95 and tumour 
necrosis factor receptor. Formation of a death-inducing signalling complex induces caspase-8 activation and 
thereby the downstream caspase cascade45. We hypothesize that the cationic DOTAP nanoaggregate, by means 
of its inherent surface charge, can interact in peculiar manner with the external surface of cell membranes, as 
suggested by the faster cellular uptake kinetics compared to POPC formulations observed in a previous study19. 
Although a hypothesis, exclusive molecular interactions coupled to local drug release could stimulate specific 
surface receptors involved in the activation of the extrinsic pathway. Indeed, not infrequently the killing of tumor 
cells by anticancer chemotherapeutics has been linked to activation of extrinsic apoptosis pathways46. These out-
comes are consistent with former investigations and demonstrate that some ruthenium(II) and (III) complexes 
can simultaneously trigger intrinsic and extrinsic apoptosis pathways47.
As far as the Bcl-2 family proteins are concerned, we believe that some central aspects closely linked to ruthe-
notherapy have emerged. Members of this family are regulatory proteins involved in the control of cell death, 
by either inducing (pro-apoptotic factors) or inhibiting (anti-apoptotic factors) apoptosis48. Bcl-2 is a crucial 
anti-apoptotic protein to be regarded as an oncogene, playing an important role in promoting cellular survival by 
inhibition of pro-apoptotic proteins. On the other hand, the pro-apoptotic effectors of the Bcl-2 family, includ-
ing Bax, normally act on the mitochondrial membrane to promote permeabilization coupled to the release of 
both cytochrome c and ROS as important signals in the apoptosis cascade. Several clinical studies have pro-
vided support for an overexpression of the antiapoptotic Bcl-2 protein as a negative prognostic marker in various 
tumours49. Alternatively, decreased Bax levels have been found in correlation with shorter survival in patients 
with breast cancer and colorectal cancer50. In MCF-7 and MDA-MB-231 we found an important effect induced 
by both DoHuRu/POPC and DoHuRu/DOTAP treatment on the cellular content of Bcl-2 and Bax, which could 
be correlated to the induction of the mitochondrial cell death pathway. The significant increase in Bax/Bcl-2 ratio 
detected in treated cells with respect to untreated cells could have an important impact in the regulation of cell 
fate by interfering with breast cancer cell survival. Indeed, in accordance with experimental and clinical investi-
gations, tumours dependent on Bcl-2 family members are likely sensitive to Bcl-2 modulation in order to survive; 
in turn high Bax expression has been associated with a better response to chemotherapy in many cancers forms51. 
Consistently with our results, it should be possible to circumvent the inherent apoptosis deficiency of malignant 
cells by directly affecting the mitochondrial function. In this way, following mechanisms yet to be clarified, the 
ruthenium complexes may interact with mitochondrial targets, possibly via selective accumulation and ROS 
generation52. At the same time, dysfunction of mitochondria might be responsible for autophagic cell death. More 
and more studies underline the important interplay between apoptosis and autophagy, and suggest that apoptosis 
activation is often related to increased autophagy processes53. As in the case of apoptosis, autophagy plays a vital 
role in cellular proliferation and survival, and dysregulated autophagy activation has been described in many 
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pathologies, including cancer. Although the role of the autophagic programmed cell death in neoplastic devel-
opment remains to be clarified in vivo, cancer cells with up-regulated autophagy exhibit a less aggressive behav-
iour as well as an increased susceptibility to chemotherapy54. Since the effectiveness of many apoptosis-inducing 
chemotherapies can be affected by specific mutations in genes orchestrating apoptotic regulation, the activation 
of alternative cell death pathways, in tandem with or in the absence of an efficient apoptotic machinery, may 
represent an attractive goal for novel metal-based chemotherapeutics. In this perspective, recent evidence sup-
ports the occurrence of the simultaneous induction of apoptosis and autophagy in cancer cells as a result of 
specific signaling55. In addition, autophagy can be also activated upon exposure to genotoxic compounds, includ-
ing several metal-based drugs able to target DNA. The induction of autophagy in the case of cationic nucleoli-
pidic formulations could be linked to the ruthenium-induced down-regulation of the prosurvival protein Bcl-2, 
evident in both MCF-7 and MDA-MD-231 cells. Indeed, disturbances in the interaction between Beclin-1 and 
Bcl-2 family proteins, by which Beclin-1 is inhibited in normal conditions, has been established to stimulate 
cellular autophagy56. Thus Ru(III) complexes activity in inhibiting breast cancer cells proliferation via DoHuRu/
DOTAP administration would lie in the crosstalk connecting the main molecular mechanisms involved in the 
regulation of apoptosis and autophagy processes. Nevertheless, the existence of other non-apoptotic nor necrotic 
cell death pathways, triggered upon exposure to ruthenium-containing nanoaggregates we have documented in 
breast cancer models, needs further and more targeted studies. According to our previous findings24 and to recent 
literature reports36,52, it cannot be excluded that the simultaneous activation of different mechanisms of cell death 
can be caused by multiple potential interactions at the subcellular/molecular level, both nuclear and cytosolic. 
Nevertheless, the activation of multiple death pathways by metal-based chemotherapeutics in aggressive cancer 
diseases with limited treatment options is a largely desired goal, in order to possibly restrict the onset of chemore-
sistance as well as to efficiently counteract uncontrolled proliferation. Upcoming investigations on the critical 
proteins and pathways involved in autophagy control exerted by Ru(III)-containing liposomes are underway to 
strengthen knowledge in favour of future in vivo applications for these high potential candidate drugs.
Methods
Cell cultures. Human breast adenocarcinoma cells, epithelial-like type as MCF-7, CG-5, MDA-MB-231 
and MDA-MB-468 lines, and pleomorphic-like type as MDA-MB-436 line, were grown in DMEM (Invitrogen, 
Paisley, UK) supplemented with 10% fetal bovine serum (FBS, Cambrex, Verviers, Belgium), L-glutamine (2 mM, 
Sigma, Milan, Italy), penicillin (100 units/ml, Sigma) and streptomycin (100 μ g/ml, Sigma), and cultured in a 
humidified 5% carbon dioxide atmosphere at 37 °C, according to ATCC recommendations. MCF-7 and CG-5 are 
endocrine-responsive (ER) breast cancers; MDA-MB-231, MDA-MB-468 and MDA-MB-436 are triple-negative 
breast cancers (TNBC)33,34. Human HaCaT keratinocytes and rat L6 skeletal muscle cells, used as healthy control 
cell lines, were grown in the same experimental conditions.
Synthesis of the ruthenium complexes ToThyRu and DoHuRu and preparation of the 
lipid-based nanoaggregates. The ruthenium complexes investigated, namely ToThyRu and DoHuRu 
(here depicted in Fig. 1 along with AziRu) were prepared by reacting in stoichiometric amounts the starting 
nucleolipids, named ToThy or DoHu57, with the Ru complex [trans-RuCl4(DMSO)2]−Na+ following a previously 
described procedure25. In all cases, the desired nucleolipidic Ru(III) complexes were obtained in a pure form, as 
confirmed by TLC and ESI-MS analysis, and almost quantitative yields. The lipid formulations of ToThyRu and 
DoHuRu in POPC and DOTAP were prepared as previously reported24 and characterized by DLS analysis.
In vitro bioscreens. The anticancer activity of ruthenium-containing nucleolipidic nanoparticles and of 
AziRu was investigated through the estimation of a “cell survival index”, arising from the combination of cell 
viability evaluation with cell counting25. Cells were inoculated in 96-microwell culture plates at a density of 104 
cells/well, and allowed to grow for 24 h. The medium was then replaced with fresh medium and cells were treated 
for further 48 h with a range of concentrations (1 → 1000 μ M) of AziRu, and of ToThyRu and DoHuRu com-
plexes lodged either in POPC or DOTAP liposomes (ToThyRu/POPC and ToThyRu/DOTAP, DoHuRu/POPC 
and DoHuRu/DOTAP, respectively). Using the same experimental procedure, cell cultures were also incubated 
with ruthenium-free ToThy/POPC, ToThy/DOTAP, DoHu/POPC and DoHu/DOTAP liposomes as negative 
controls, as well as with cisplatin (cDDP) - a positive control for cytotoxic effects27. Cell viability was evaluated 
using the MTT assay procedure, which measures the level of mitochondrial dehydrogenase activity using the 
yellow 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, Sigma) as substrate. The assay 
is based on the redox ability of living mitochondria to convert dissolved MTT into insoluble purple formazan. 
Briefly, after the treatments, the medium was removed and the cells were incubated with 20 μ l/well of a MTT solu-
tion (5 mg/mL) for 1 h in a humidified 5% CO2 incubator at 37 °C. The incubation was stopped by removing the 
MTT solution and by adding 100 μ l/well of DMSO to solubilize the obtained formazan. Finally, the absorbance 
was monitored at 550 nm using a microplate reader (iMark microplate reader, Bio-Rad, Milan, Italy). Cell number 
was determined by TC10 automated cell counter (Bio-Rad, Milan, Italy), providing an accurate and reproducible 
total count of cells and a live/dead ratio in one step by a specific dye (trypan blue) exclusion assay. Bio-Rad’s TC10 
automated cell counter uses disposable slides, TC10 trypan blue dye (0.4% trypan blue dye w/v in 0.81% sodium 
chloride and 0.06% potassium phosphate dibasic solution) and a CCD camera to count cells based on the analyses 
of captured images. Once the loaded slide is inserted into the slide port, the TC10 automatically focuses on the 
cells, detects the presence of trypan blue dye and provides the count. When cells are damaged or dead, trypan 
blue can enter the cell allowing living cells to be counted. Operationally, after treatments in 96-microwell culture 
plates, the medium was removed and the cells were collected. Ten microliters of cell suspension, mixed with 0.4% 
trypan blue solution at 1:1 ratio, were loaded into the chambers of disposable slides. The results are expressed in 
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terms of total cell count (number of cells per ml). If trypan blue is detected, the instrument also accounts for the 
dilution and shows live cell count and percent viability. Total counts and live/dead ratio from random samples for 
each cell line were subjected to comparisons with manual hemocytometers in control experiments.
The calculation of the concentration required to inhibit the net increase in the cell number and viability by 
50% (IC50) is based on plots of data (n = 6 for each experiment) and repeated five times (total n = 30). IC50 values 
were obtained by means of a concentration response curve by nonlinear regression using a curve fitting program, 
GraphPad Prism 5.0, and are expressed as mean values ± SEM (n = 30) of five independent experiments.
Cell morphology. Human breast cancer cell lines were grown on 60 mm culture dishes by plating 
5 × 105 cells. After reaching the subconfluence, cells were incubated for 48 h with IC50 concentrations of the 
ruthenium-containing liposomes (DoHuRu/POPC and DoHuRu/DOTAP) under the same in vitro experimental 
conditions described above and were then morphologically examined by a phase-contrast microscope (Labovert 
microscope, Leizt) for autophagic vacuoles and apoptotic markers. Microphotographs at a 200 × total magnifica-
tion (20 × objective and 10 × eyepiece) were taken with a standard VCR camera (Nikon).
DNA fragmentation assay. MCF-7 and MDA-MB-231 cells were grown on standard plastic 60 mm culture 
dishes by plating 5 × 105 cells. After 24 h of growth the cells were treated for 48 h with IC50 doses of DoHuRu/
POPC and DoHuRu/DOTAP liposomes under the same experimental conditions described for bioscreens, as 
well as with IC50 doses of cisplatin (cDDP) - a positive control for in vitro apoptosis29. The DNA fragmentation 
assay was carried out as previously reported27. After treatments, cells were collected and the pellets were sus-
pended in lysis buffer (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 100 mM NaCl, 1% SDS, 0.5 mg/mL Proteinase 
K) and incubated at 50 °C. After 1 h incubation, 10 mg/mL RNase was added to the lysates and incubated for 1 h 
at 50 °C. DNA was precipitated with NaOAc pH 5.2 and ice cold 100% EtOH and centrifuged at 14000 × g for 
10 min. Pellets were dissolved in TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). A 20 μ L aliquot of each DNA 
sample was analyzed on a 1.5% agarose gel stained with ethidium bromide and visualized under UV light.
FACS analysis. Annexin V-FITC (fluorescein isothiocyanate) was used in conjunction with a vital dye, 
propidium iodide (PI), to differentiate apoptotic (Annexin V-FITC positive, PI negative) from necrotic (Annexin 
V-FITC positive, propidium iodide positive) cells58. Briefly, cells were incubated with Annexin V–FITC 
(MedSystems Diagnostics, Vienna, Austria) and propidium iodide (Sigma, St. Louis, MO, USA) in a binding 
buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2) for 10 min at room tem-
perature, washed and resuspended in the same buffer. Analysis of apoptotic cells was performed by flow cytom-
etry (FACScan, Becton 4 Dickinson)59. For each sample, 2 × 104 events were acquired. The study was carried out 
by triplicate determination on at least three separate experiments.
Labeling of autophagic vacuoles with monodansylcadaverine (MDC). To quantify the induction 
of the autophagic process, MCF-7 and MDA-MB-231 cells, treated with IC50 concentrations of the DoHuRu/
POPC and DoHuRu/DOTAP formulations, were stained with the autofluorescent agent monodansylcadaverine 
(MDC), a selective marker for autophagic vacuoles (AVOs), especially for autolysosomes60. Treated cells were 
incubated with 50 μ M MDC in PBS at 37 °C for 15 min. After incubation, cells were washed twice with PBS, and 
immediately analyzed by flow cytometry with a FACScalibur flow cytometer (Becton Dickinson). The fluorescent 
emissions were collected through a 530 nm band pass filter (FL1 channel). At least 104 events were acquired in 
log mode. For the quantitative evaluation of MDC, CellQuest software (Becton Dickinson) was used to calculate 
mean fluorescence intensities (MFIs). The MFIs were calculated by the formula (MFI treated/MFI control), where 
MFI treated is the fluorescence intensity of cells treated with the various compounds and MFI control is the flu-
orescence intensity of untreated and unstained cells. Values reported in the figures are the mean values ± SEM 
from three independent experiments.
Preparation of cellular extracts. MCF-7 and MDA-MB-231 cells were cultured in standard plastic 60 mm 
culture dishes by plating 5 × 105 cells. Behind reaching the subconfluence, cells were incubated for 48 and 72 h 
with IC50 concentrations of the ruthenium-containing liposomes (DoHuRu/POPC and DoHuRu/DOTAP) under 
the same experimental conditions herein described. After treatments, cells were washed and collected by scraping 
with PBS containing 1 mM EDTA and low-speed centrifugation. Cell pellets were then lysed at 4 °C for 30 min 
in a buffer containing 20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 5% (v/v) glycerol, 10 mM NP-40 
and protease inhibitor tablets (Roche)61. The supernatant fraction was obtained by centrifugation at 15,000 × g 
for 10 min at 4 °C and then stored at − 80 °C. Protein concentration was determined by the Bio-Rad protein assay 
(Bio-Rad, Milan, Italy).
Western blot analysis. For Western blot analysis, samples containing 30–50 μ g of proteins were loaded on 
10% SDS–PAGE and transferred to nitrocellulose membranes62,63. After blocking at room temperature in milk 
buffer [1 × PBS, 5–10% (w/v) non-fat dry milk, 0.2% (v/v) Tween-20], the membranes were incubated at 4 °C 
overnight with: 1:500 rabbit polyclonal antibody to human caspase-8 (Santa Cruz Biotechnology, Santa Cruz, 
CA); 1:500 mouse monoclonal antibody to human caspase-9 (Santa Cruz Biotechnology); 1:500 rabbit polyclonal 
antibody to human caspase-3 (Santa Cruz Biotechnology); 1:500 rabbit polyclonal antibody to human Bcl-2 
(26 kDa) (Santa Cruz Biotechnology); 1:250 rabbit polyclonal antibody to human Bax (Santa Cruz Biotechnology, 
Santa Cruz). Subsequently, the membranes were incubated with peroxidase-conjugated goat anti-rabbit IgG, 
or with peroxidase-conjugated goat anti-mouse IgG + IgM (all the secondary antibodies were purchased from 
Jackson ImmunoResearch Laboratories). The resulting immunocomplexes were visualized by the ECL chemo-
luminescence method (ECL, Amersham Biosciences Little Chalfont, Buckinghamshire, UK) and analyzed by 
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an imaging system (ImageQuantTM400, GE Healthcare Life Sciences)64. Densitometric analysis was conducted 
using the GS-800 imaging densitometer (Bio-Rad)65. Normalization of results was ensured by incubating the 
nitrocellulose membranes in parallel with the tubulin antibody (Sigma-Aldrich).
Statistical Analysis. All data were presented as mean values ± SEM. The statistical analysis was performed 
using Graph-Pad Prism (Graph-Pad software Inc., San Diego, CA) and ANOVA test for multiple comparisons 
was performed followed by Bonferroni’s test.
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